252
Articles
11.1K
Citations
3.5
avg. Impact Factor
45
h-index

Most Cited Articles of Department of Hematology and Medical Oncology in 2015

TitleJournalYearCitations
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNetLeukemia201553
Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancerOncotarget201530
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancerEuropean Journal of Cancer201526
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxideBritish Journal of Haematology201526
Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessaryDiseases of the Colon and Rectum201524
Functional patterns of cytomegalovirus (CMV) pp65 and immediate early-1-specific CD8(+) T cells that are associated with protection from and control of CMV DNAemia after allogeneic stem cell transplantationTransplant Infectious Disease201521
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trialAnnals of Oncology201518
FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium studyGut201517
Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipientsTransplant Infectious Disease201517
Incidence and dynamics of active cytomegalovirus infection in allogeneic stem cell transplant patients according to single nucleotide polymorphisms in donor and recipient CCR5, MCP-1, IL-10, and TLR9 genesJournal of Medical Virology201517
Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C TrialInternational Journal of Radiation Oncology Biology Physics201513
GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC).Journal of Clinical Oncology201510
The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell TransplantationPLoS ONE20158
Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatmentClinical and Translational Oncology20157
BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemiaLeukemia Research20155
Enumeration of NKG2C+ natural killer cells early following allogeneic stem cell transplant recipients does not allow prediction of the occurrence of cytomegalovirus DNAemiaJournal of Medical Virology20154
Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature reviewOncoTargets and Therapy20154
2748 Assessment of associations between disease stage and toxicity with bevacizumab (BEV) in ICON7, a phase III trial of front-line carboplatin/paclitaxel (CP) ± BEV for ovarian cancer (OC)European Journal of Cancer20152
Critical evaluation of the scientific content in clinical practice guidelinesCancer20152
Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).Journal of Clinical Oncology20152
Extending neoadjuvant chemotherapy in rectal cancerLancet Oncology, The20151
Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial.Journal of Clinical Oncology20151
Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).Journal of Clinical Oncology20151